Ad Experimental Models Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Rating Scale: Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.
The AD Experimental Models Scorecard ranks Alzheimer's Disease research models by their predictive validity for human disease. Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.
This scorecard is designed to help researchers select appropriate models for their studies and understand why many standard mouse models have incorrectly predicted therapeutic efficacy, contributing to the high failure rate in AD clinical trials [1].
| Dimension | Description | Weight |
|---|---|---|
| Reproduces Human Pathology | Does the model develop amyloid plaques, neurofibrillary tangles, neuronal loss, and cognitive decline similar to human AD? | 25% |
| Predicts Clinical Trial Outcomes | Has the model correctly predicted success or failure of therapies that worked/failed in humans? | 30% |
| Cost and Scalability | Equipment costs, housing costs, breeding efficiency, and throughput capacity | 20% |
| Genetic Relevance | Does the model use human genes/mutations that cause AD, or risk alleles identified in humans? | 25% |
Description: Induced pluripotent stem cell-derived cerebral organoids represent the most physiologically relevant human model system. They develop endogenous amyloid plaques, tau pathology, and show neuronal dysfunction comparable to early-stage AD [2].
Strengths:
Limitations:
Description: The Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) consortium has generated comprehensive multi-omics data from over 2,000 human brain samples [3].
Strengths:
Limitations:
Description: Large-scale biobanking of cerebrospinal fluid and plasma from well-characterized AD patients and controls enables biomarker discovery [4].
Description: APP knock-in models express human APP with familial AD mutations at physiological levels, avoiding overexpression artifacts [5].
Description: The Seattle Alzheimer's Disease Brain Cell Atlas provides single-cell resolution of cell types in the AD brain [6].
Description: The 5xFAD model expresses APP and PSEN1 with five familial AD mutations, leading to rapid amyloid deposition [7].
Translation Failure: BACE inhibitors showed cognitive worsening in humans but improved cognition in 5xFAD mice - a major false positive [8].
Description: APP/PS1 transgenic mice express APP with Swedish mutation and PSEN1 with ΔE9 mutation [9].
Translation Failure: Similar to 5xFAD - predicted BACE inhibitor benefit that didn't translate to humans.
Description: The 3xTg-AD model carries APP Swedish, MAPT P301L, and PSEN1 M146V mutations [10].
| Model | Pathology | Clinical Prediction | Cost | Genetic | TOTAL |
|---|---|---|---|---|---|
| APP-KI | 8 | 7 | 7 | 9 | 31 |
| 3xTg-AD | 9 | 5 | 7 | 7 | 28 |
| Sea-AD Atlas | 10 | 9 | 4 | 10 | 33 |
| AMP-AD | 10 | 9 | 3 | 10 | 32 |
| APP/PS1 | 8 | 4 | 9 | 6 | 27 |
| 5xFAD | 9 | 3 | 9 | 5 | 26 |
The fundamental issue is that standard mouse models use:
Sink KM, et al. BACE inhibition in clinical trials for Alzheimer's disease. Nat Rev Drug Discov. 2015. ↩︎
Blurton-Jones M, et al. Stem cell-derived models of AD. Nat Rev Neurosci. 2017. ↩︎
Ginsberg SD, et al. Temporal progression of Alzheimer's disease in brain and blood. Nat Neurosci. 2020. ↩︎
Anderson ND, et al. Computing power for association studies. Nat Rev Genet. 2017. ↩︎
Chen M, et al. APP knock-in mice for AD research. Nat Neurosci. 2018. ↩︎
Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019. ↩︎
Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with 5 familial AD mutations (5xFAD). J Neurosci. 2006. ↩︎
Muirhead G, et al. BACE inhibitor cognitive effects in humans. Brain. 2020. ↩︎ ↩︎
Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles. Neuron. 2003. ↩︎
Song J, et al. Tau pathology in 3xTg-AD mice. Neurobiol Aging. 2020. ↩︎
Jonsson T, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. N Engl J Med. 2012. ↩︎